柳药集团 (603368)
Guangxi LiuYao Group Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 39716.89
- Circulating A-Shares(W): 39716.89
- Earnings Per Share(RMB): 1.6300
- Net Assets Per Share(RMB): 19.3168
- Operating Revenue(W RMB): 1575803.67
- Total Profit(W RMB): 74851.22
- **Net Profit Attributable to Parent(W RMB) **: 64571.31
- Net Profit Growth Rate(%): -9.81
- Weighted Return on Equity(%): 8.2400
- Operating Cash Flow Per Share(RMB): 0.3410
- Undistributed Profit Per Share(RMB): 12.2536
- Capital Reserve Per Share(RMB): 5.7285
2. Main Business
The main business covers:
- Wholesale and retail of pharmaceutical products such as drugs and medical devices
3. Company Basic Information
- Company Name: Guangxi Liuzhou Pharmaceutical Group Co., Ltd.
- Listing Date: 2014-12-04
- Industry: Medicine and Healthcare - Pharmaceutical Commerce (TDX Research Industry); Wholesale Industry (CSRC Industry)
- Address: No. 68 Guantang Avenue, Liuzhou City, Guangxi Zhuang Autonomous Region
- Website: https://www.lzyy.cn
- Company Profile: The company was established by Guangxi Liuzhou Pharmaceutical Co., Ltd. through an overall change into a joint stock company. Approved by the Guangxi Department of Commerce's "Reply on Approving the Change of Guangxi Liuzhou Pharmaceutical Co., Ltd. into a Joint Stock Enterprise" (Gui Shang Zi Han [2011] No. 18), the company used all shareholders of Liuzhou Pharmaceutical Co., Ltd. as promoters. Based on the net assets of 176,489,481.52 yuan audited by Zhongqin Wanxin as of December 31, 2010, the net assets were converted into 90,000,000 shares of the joint stock company's share capital at a ratio of 1:0.509945, with a par value of 1 yuan per share. The portion of net assets exceeding the total share capital, 86,489,481.52 yuan, was included in the capital reserve. The promoters held the corresponding number of shares according to their respective capital contribution ratios in Liuzhou Pharmaceutical Co., Ltd. On February 23, 2011, the company obtained the "Approval Certificate for Enterprises with Investment from Taiwan, Hong Kong, Macao, and Overseas Chinese" with approval number Shang Wai Zi Gui He Zi Zi [2010] No. 0147. On February 28, 2011, the company completed the industrial and commercial establishment registration at the Liuzhou Administration for Industry and Commerce and obtained the "Business License of Enterprise Legal Person" with registration number 450200200002273.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Guangdong Hengjian International Investment Co., Ltd. | General Legal Person | 1052.63 | 2.65 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 440.21 | 1.11 |
| 3 | Southern China Securities 1000 ETF | Fund | 292.24 | 0.74 |
| 4 | Fude Property Insurance Co., Ltd. - Own Funds | Insurance | 266.32 | 0.67 |
| 5 | Chutong Advantage Industry Rotation Mixed Securities Investment Fund Class A | Fund | 135.49 | 0.34 |
| 6 | Chutong Science and Innovation Theme Flexible Allocation Mixed Securities Investment Fund (LOF) | Fund | 76.36 | 0.19 |
| 7 | Chutong Science and Technology Innovation Mixed Securities Investment Fund Class A | Fund | 53.78 | 0.14 |
| 8 | Hongtu Innovation Stable Mixed Securities Investment Fund Class A | Fund | 17.68 | 0.04 |
| 9 | Chutong Fusheng Multi-Strategy Mixed Initiation Securities Investment Fund (LOF) Class A | Fund | 11.36 | 0.03 |
| 10 | Yongying Xinsheng Mixed Securities Investment Fund Class A | Fund | 2.00 | 0.01 |
5. Concept Sectors
- Convertible Bonds
- Baby Concept
- Smart Healthcare
- Artificial Intelligence
- Cold Chain Logistics
- Hepatitis Concept
- Innovative Drugs
- Margin Trading & Securities Lending
- Low P/E Ratio
- High-Performing Stocks
- Below Net Asset Value
- Share Buyback Plan
- High Accounts Receivable
- Guoxin Value
- SSE 580
Remarks
- Data update date: 2025-11-04
- Data source: Public Market Information